Early drug study aims to understand BI 1839100's journey in the body
NCT ID NCT06572111
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial in 8 healthy men aims to understand how the experimental drug BI 1839100 is processed by the body. Part A tracks the drug and its radioactive label in urine and feces after an oral dose. Part B compares how much of the drug reaches the bloodstream when given orally versus intravenously. The study is terminated, so results may be limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BI 1839100
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ICON-Groningen-62040
Groningen, 9728 NZ, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test